Desformylflustrabromine

Desformylflustrabromine
Desformylflustrabromine
Systematic (IUPAC) name
2-[6-bromo-2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]-N-methylethanamine
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 474657-72-2
ATC code None
PubChem CID 637026
Chemical data
Formula C16H21BrN2 
Mol. mass 321.254 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Desformylflustrabromine (dFBr) is a tryptamine derivative which was first isolated as an active metabolite of the marine bryozoan Flustra foliacea.[1]

Bioactivity

dFBr has been identified as a novel positive allosteric modulator of neuronal nicotinic acetylcholine receptor with sub-type specificity for heteromeric receptor with no effect on homomeric sub-type.[2] A recent study has been published which describes the synthesis of water-soluble salts of dFBr and its action has been confirmed as selective potentiator of α4β2 nicotinic acetylcholine receptor responses by using two-electrode voltage clamp whole cell recordings.[3] In the year 2002 it was reported that dFBr was cytotoxic on human colon cancer cell line HCT-116. [4] Desformylflustrabromine has also been found to be a positive allosteric modulator for the α2β2 subtype of neuronal nicotinic acetylcholine receptor. Additionally it relieves the inhibition of both α2β2 and α4β2 Nicotinic Acetylcholine Receptors by β-Amyloid (1–42) Peptide.[5] Thus Desformylflustrabromine can potentially be used in the treatment of Alzheimer’s disease. Many of the deconstructed analogs of dFBr are reported to have a potentiating effect on the α4β2 receptors.[6]

References

  1. ^ Peters, L.; Wright, A. D.; Kehraus, S.; Gündisch, D.; Tilotta, M. C.; König, G. M. Planta Medica. 2004, 70, 883.
  2. ^ Sala F, Mulet J, Reddy KP, Bernal JA, Wikman P, Valor LM, Peters L, König GM, Criado M, Sala S. Potentiation of human alpha4beta2 neuronal nicotinic receptors by a Flustra foliacea metabolite. Neuroscience Letters. 2005 Jan 10;373(2):144-9. PMID 15567570
  3. ^ Jin-Sung Kim, Anshul Pandya, Maegan Weltzin, Brian W. Edmonds, Marvin K. Schulte, and Richard A. Glennon. Synthesis of desformylflustrabromine and its evaluation as an alpha4beta2 and alpha7 nACh receptor modulator. Bioorganic and Medicinal Chemistry Letters. 2007 Sep 1;17(17):4855-60. doi:10.1016/j.bmcl.2007.06.047
  4. ^ Lysek N, Rachor E, Lindel T. Isolation and structure elucidation of deformylflustrabromine from the North Sea bryozoan Flustra foliacea. Zeitschrift zur Naturforschung [C]. 2002 Nov-Dec;57(11-12):1056-61. PMID 12562094
  5. ^ Pandya A, Yakel J. Allosteric Modulator Desformylflustrabromine Relieves the Inhibition of α2β2 and α4β2 Nicotinic Acetylcholine Receptors by β-Amyloid1–42 Peptide. J Mol Neurosci. 2011 Mar 22
  6. ^ Nadezhda German , Jin-Sung Kim , Atul Jain, Malgorzata Dukat, Anshul Pandya, Yilong Ma, Maegan Weltzin, Marvin K. Schulte, and Richard A. Glennon. Deconstruction of the α4β2 Nicotinic Acetylcholine (nACh) Receptor Positive Allosteric Modulator des-Formylflustrabromine (dFBr). Journal of Medicinal Chemistry. 2011 2011 Sep 9. [Epub ahead of print]